141 related articles for article (PubMed ID: 7513532)
1. Neoadjuvant androgen blockade prior to prostatectomy: a retrospective study and critical review.
Schulman CC
Prostate Suppl; 1994; 5():9-14. PubMed ID: 7513532
[TBL] [Abstract][Full Text] [Related]
2. PSA levels and the rate of positive surgical margins in radical prostatectomy specimens preceded by androgen blockade in clinical B2 (T2bNxMo) prostate cancer. The Lupron Depot Neoadjuvant Study Group.
McLeod DG; Johnson CF; Klein E; Peabody JO; Coffield S; Soloway M
Urology; 1997 Mar; 49(3A Suppl):70-3. PubMed ID: 9123740
[TBL] [Abstract][Full Text] [Related]
3. 4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Schulman CC; Debruyne FM; Forster G; Selvaggi FP; Zlotta AR; Witjes WP
Eur Urol; 2000 Dec; 38(6):706-13. PubMed ID: 11111188
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Clin Invest Med; 1993 Dec; 16(6):523-31. PubMed ID: 7516836
[TBL] [Abstract][Full Text] [Related]
5. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.
Witjes WP; Schulman CC; Debruyne FM
Urology; 1997 Mar; 49(3A Suppl):65-9. PubMed ID: 9123739
[TBL] [Abstract][Full Text] [Related]
6. Hormone therapy prior to radical prostatectomy in patients with clinical stage C prostate cancer.
Voges GE; Mottrie AM; Stöckle M; Müller SC
Prostate Suppl; 1994; 5():4-8. PubMed ID: 7513531
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant hormonal deprivation before radical prostatectomy.
Sassine AM; Schulman CC
Eur Urol; 1993; 24 Suppl 2():46-50. PubMed ID: 7505231
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant hormonal deprivation before radical prostatectomy.
Schulman CC; Sassine AM
Eur Urol; 1993; 24(4):450-5. PubMed ID: 7507045
[TBL] [Abstract][Full Text] [Related]
9. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results.
Fair WR; Cookson MS; Stroumbakis N; Cohen D; Aprikian AG; Wang Y; Russo P; Soloway SM; Sogani P; Sheinfeld J; Herr H; Dalgabni G; Begg CB; Heston WD; Reuter VE
Urology; 1997 Mar; 49(3A Suppl):46-55. PubMed ID: 9123736
[TBL] [Abstract][Full Text] [Related]
10. [Effect of complete androgen block before radical prostatectomy for cancer of the prostate].
Gómez Veiga F; Lorenzo Patiño MJ; Díaz Bermúdez J; Duarte Novo J; Alvarez Castelo L; Chantada Abal V; Sánchez Rodríguez J; González Martín M
Arch Esp Urol; 1997 May; 50(4):355-63. PubMed ID: 9313044
[TBL] [Abstract][Full Text] [Related]
11. High failure rate associated with long-term follow-up of neoadjuvant androgen deprivation followed by radical prostatectomy for stage C prostatic cancer.
Cher ML; Shinohara K; Breslin S; Vapnek J; Carroll PR
Br J Urol; 1995 Jun; 75(6):771-7. PubMed ID: 7542137
[TBL] [Abstract][Full Text] [Related]
12. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group.
Soloway MS; Sharifi R; Wajsman Z; McLeod D; Wood DP; Puras-Baez A
J Urol; 1995 Aug; 154(2 Pt 1):424-8. PubMed ID: 7541859
[TBL] [Abstract][Full Text] [Related]
13. Update on Memorial Sloan-Kettering Cancer Center studies of neoadjuvant hormonal therapy for prostate cancer.
Fair WR; Betancourt JE
Mol Urol; 2000; 4(3):241-8;discussion 249-50. PubMed ID: 11062380
[TBL] [Abstract][Full Text] [Related]
14. Induction androgen deprivation plus prostatectomy for stage T3 disease: failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial.
Gomella LG; Liberman SN; Mulholland SG; Petersen RO; Hyslop T; Corn BW
Urology; 1996 Jun; 47(6):870-7. PubMed ID: 8677579
[TBL] [Abstract][Full Text] [Related]
15. The limited significance of a longer duration of neoadjuvant hormonal therapy prior to radical prostatectomy for high-risk prostate cancer in Japanese men.
Miyake H; Sakai I; Inoue TA; Hara I; Fujisawa M
Urol Int; 2006; 77(2):122-6. PubMed ID: 16888415
[TBL] [Abstract][Full Text] [Related]
16. Effects of androgen deprivation prior to radical prostatectomy in 375 patients.
Tunn UW; Acar O; Goldschmidt AJ
Urol Int; 1996; 56 Suppl 1():6-12. PubMed ID: 8776811
[TBL] [Abstract][Full Text] [Related]
17. Clinical and pathobiological effects of neoadjuvant total androgen ablation therapy on clinically localized prostatic adenocarcinoma.
Armas OA; Aprikian AG; Melamed J; Cordon-Cardo C; Cohen DW; Erlandson R; Fair WR; Reuter VE
Am J Surg Pathol; 1994 Oct; 18(10):979-91. PubMed ID: 7522415
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant hormonal deprivation for patients undergoing radical prostatectomy.
Gao X; Zhou T; Tang YJ; Lu X; Sun YH
Asian J Androl; 2009 Jan; 11(1):127-30. PubMed ID: 19050694
[TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
Soloway MS; Hachiya T; Civantos F; Murphy WM; Gomez CC; Ruiz HE
Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
[TBL] [Abstract][Full Text] [Related]
20. Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
Voges GE; Mottrie AM; Fichtner J; Mappes C; Störkel S; Stöckle M; Hohenfellner R
Eur Urol; 1995; 28(3):209-14. PubMed ID: 8536774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
